IP Library › Granted Patent US 10,266,805
Granted Patent B2
US 10,266,805 · App. 15/357,029 · Granted Apr 23, 2019

Human progenitor T-cells into NK cells

Inventors: Juan Carlos Zuniga-Pflucker (Toronto, CA); Geneve Awong (North York, CA); Ross La Motte-Mohs (Germantown, MD)
Assignee: Sunnybrook Health Sciences Centre
C12N5/0647A61K35/17C12N5/0636C12N5/0646G01N33/5005A61K2035/124C12N5/0663C12N5/0669C12N2501/2302C12N2501/2307C12N2501/2315C12N2501/42C12N2502/13C12N2502/1305C12N2502/137C12N2502/1311C12N2502/1317C12N2502/1323C12N2502/1329C12N2502/1335C12N2502/1341C12N2502/1347C12N2502/1352C12N2502/1358C12N2502/1364C12N2502/1376C12N2502/1382C12N2502/1388C12N2502/1394C12N2502/99C12N2506/02C12N2506/11C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,266,805
App. No.
15/357,029
Granted
Apr 23, 2019
Kind
B2
Abstract

Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.

Claims (5)

1. A method of generating natural killer (NK) cells comprising a) preparing T progenitor cells having the phenotype CD34 + CD7 + CD5 + CD1a − by culturing stem cells or progenitor cells selected from the group consisting of hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells with stromal cells and isolating the progenitor T cells, b) culturing the isolated T progenitor cells with IL-15 or IL-2 and c) isolating NK cells.

2. The method of claim 1 wherein the hematopoietic stem cell (HSC) is a human HSC.

3. The method of claim 1 wherein the stromal cells express a Notch ligand.

4. The method according to claim 3 wherein the Notch ligand is DL1 or DL4.

5. The method of claim 4 wherein the stromal cell expressing the Notch ligand is an OP-9 cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2016
From: ZUNIGA-PFLUCKER, JUAN CARLOS; AWONG, GENEVE SHEANDRA; LA MOTTE-MOHS, ROSS
To: SUNNYBROOK HEALTH SCIENCES CENTRE
Reel/Frame 040398/0424 →
Continuity (4)
Continuation 14284533 · May 22, 2014
Continuation 13127490
Provisional Application 61112503 · Nov 7, 2008
Related Publication 20170121684A1 · May 4, 2017
Cited By (1)
US 12,269,888